TrialSignal
Clinical trial intelligence report
A 12-week, Phase 2, Randomized, Double-blind, Placebo Controlled, Dose-ranging, Parallel Group Study to Evaluate the Efficacy and Safety of Twice Daily Pf-04991532 and Once Daily Sitagliptin in Adult Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin
Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.
Generated
Jun 25, 2026
Report code
NCT01338870-Jun 25, 2026
NCT ID
NCT01338870
Status
COMPLETED
Phase
Phase 2
Sponsor
Pfizer
Executive brief
Investment-Ready Snapshot
PF-04991532 is being evaluated as a novel treatment option for adults with Type 2 diabetes inadequately controlled on metformin. The competitive landscape includes established therapies such as sitagliptin, which may limit market entry unless PF-04991532 demonstrates superior efficacy or safety. The Phase 2 results will be critical for informing further development and potential partnerships or licensing opportunities. Given the growing prevalence of diabetes, successful outcomes could position PF-04991532 favorably in a lucrative market segment.
Source & freshness
Provenance
https://clinicaltrials.gov/study/NCT01338870
Indication
Diabetes Mellitus, Type 2
Modality
small molecule
Target
PF-04991532 is an investigational medication targeting glucose regulation in Type 2 diabetes mellitus, potentially acting on incretin pathways similar to DPP-4 inhibitors.
Intervention
Placebo, 25 mg PF-04991532, 75 mg PF-04991532, 150 mg PF-04991532, 300 mg PF-04991532, Sitagliptin 100 mg
Source record
Protocol Description
Detailed source ingestion pending.
Source record
Outcome Measures
Detailed source ingestion pending.
Source record
Eligibility
Detailed source ingestion pending.
AI analysis
Known Results And Readout Context
Detailed source ingestion pending.
IP intelligence
Patent And IP Landscape
Detailed source ingestion pending.
Source record
Contacts
Detailed source ingestion pending.